LevoVil AM Tablet is a combination medication containing Ambroxol 75 mg, Levocetirizine 5 mg, and Montelukast 10 mg, formulated to provide comprehensive relief from respiratory conditions characterized by cough, allergic rhinitis, and bronchial asthma. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of mucus from the respiratory tract, thereby improving airway patency and reducing cough severity. Levocetirizine, a potent second-generation antihistamine, selectively antagonizes peripheral H1 receptors, effectively alleviating symptoms of allergic rhinitis such as sneezing, nasal congestion, and itching without causing significant sedation. Montelukast, a leukotriene receptor antagonist, inhibits the action of cysteinyl leukotrienes, which are key mediators in airway inflammation and bronchoconstriction, thus contributing to the prevention and management of asthma symptoms and exercise-induced bronchospasm. The synergistic action of these three active ingredients makes LevoVil AM Tablet suitable for patients requiring multi-faceted treatment targeting mucus hypersecretion, allergic manifestations, and airway inflammation. It is recommended to be used under medical supervision, with dosage and duration tailored to individual clinical needs. Caution is advised in patients with hepatic impairment or hypersensitivity to any component.